363 related articles for article (PubMed ID: 28412197)
21. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS.
Bouchet S; Chauzit E; Ducint D; Castaing N; Canal-Raffin M; Moore N; Titier K; Molimard M
Clin Chim Acta; 2011 May; 412(11-12):1060-7. PubMed ID: 21345336
[TBL] [Abstract][Full Text] [Related]
22. Resistance to BRAF-targeted therapy in melanoma.
Sullivan RJ; Flaherty KT
Eur J Cancer; 2013 Apr; 49(6):1297-304. PubMed ID: 23290787
[TBL] [Abstract][Full Text] [Related]
23. Trametinib (MEKINIST°) Metastatic or inoperable BRAF V600-positive melanoma: a few extra months of life.
Prescrire Int; 2016 Dec; 25(177):285-288. PubMed ID: 30758923
[TBL] [Abstract][Full Text] [Related]
24. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
[TBL] [Abstract][Full Text] [Related]
25. What impact will BRAF/MEK-inhibitors have on the melanoma treatment armamentarium and are there challenges ahead?
Rutkowski P; Rogala P
Expert Opin Pharmacother; 2023; 24(10):1101-1103. PubMed ID: 37144819
[No Abstract] [Full Text] [Related]
26. Development and validation of a rapid and simple LC-MS/MS method for quantification of vemurafenib in human plasma: application to a human pharmacokinetic study.
Bihan K; Sauzay C; Goldwirt L; Charbonnier-Beaupel F; Hulot JS; Funck-Brentano C; Zahr N
Ther Drug Monit; 2015 Feb; 37(1):132-6. PubMed ID: 24977381
[TBL] [Abstract][Full Text] [Related]
27. Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS.
Krens SD; van der Meulen E; Jansman FGA; Burger DM; van Erp NP
Biomed Chromatogr; 2020 Mar; 34(3):e4758. PubMed ID: 31758580
[TBL] [Abstract][Full Text] [Related]
28. BRAF/MEK inhibitor-associated nephrotoxicity in a real-world setting and human kidney cells.
Sanagawa A; Hotta Y; Mori N; Tomita N; Kataoka T; Tohkin M; Kimura K
Anticancer Drugs; 2021 Nov; 32(10):1076-1083. PubMed ID: 34232935
[TBL] [Abstract][Full Text] [Related]
29. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
[TBL] [Abstract][Full Text] [Related]
30. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
Queirolo P; Picasso V; Spagnolo F
Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
32. Targeted therapies for cutaneous melanoma.
Kee D; McArthur G
Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
Dudnik E; Bar J; Peled N; Bshara E; Kuznetsov T; Cohen AY; Shochat T; Nechushtan H; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadar N; Urban D; Mishaeli M; Rabinovich NM; Brenner R; Zer A; Rotem O; Roisman LC; Wollner M;
Clin Lung Cancer; 2019 Jul; 20(4):278-286.e1. PubMed ID: 31060855
[TBL] [Abstract][Full Text] [Related]
35. The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.
Akabane H; Sullivan RJ
Am J Clin Dermatol; 2016 Feb; 17(1):1-10. PubMed ID: 26518880
[TBL] [Abstract][Full Text] [Related]
36. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
37. [Treatment combinations in BRAF-mutant metastatic melanoma.].
Depenni R
Recenti Prog Med; 2021 Apr; 112(4):40e-43e. PubMed ID: 33877098
[TBL] [Abstract][Full Text] [Related]
38. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
Gogas HJ; Flaherty KT; Dummer R; Ascierto PA; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Sileni VC; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Gollerkeri A; Pickard MD; Robert C
Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754
[TBL] [Abstract][Full Text] [Related]
39. Targeted Therapy for Melanoma.
Wong DJ; Ribas A
Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
[TBL] [Abstract][Full Text] [Related]
40. Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma.
Consoli F; Bersanelli M; Perego G; Grisanti S; Merelli B; Berruti A; Petrelli F
Clin Transl Oncol; 2020 Jun; 22(6):900-907. PubMed ID: 31555967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
